Fontolizumab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized(frommouse) |
| Target | interferon gamma |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Molar mass | ca. 150 kg/mol |
  (what is this?)(verify) | |
Fontolizumab(planned trade nameHuZAF) is ahumanized monoclonal antibody[1]and animmunosuppressive drugfor the treatment ofauto-immune diseaseslikeCrohn's disease.[2]A phase IIclinical trialinvestigating the use forrheumatoid arthritiswas terminated because the first phase did not meet theendpoint.[3]
References[edit]
- ^Statement On A Nonproprietary Name Adopted By The Usan Council - Fontolizumab,American Medical Association.
- ^Reinisch W, de Villiers W, Bene L, Simon L, Rácz I, Katz S, et al. (February 2010)."Fontolizumab in moderate to severe Crohn's disease: a phase 2, randomized, double-blind, placebo-controlled, multiple-dose study".Inflammatory Bowel Diseases.16(2): 233–42.doi:10.1002/ibd.21038.PMID19637334.S2CID25337474.
- ^Clinical trial numberNCT00281294for "A Phase 2 Study to Evaluate the Safety, Tolerability, and Activity of Fontolizumab in Subjects With Active Rheumatoid Arthritis" atClinicalTrials.gov
 | Thismonoclonal antibody–related article is astub.You can help Wikipedia byexpanding it. |
 | Thisantineoplasticorimmunomodulatorydrugarticle is astub.You can help Wikipedia byexpanding it. |